About US
Contact us
-
AstraZeneca and Merck announce full results for PARP inhibitor LynparzaAstraZeneca and Merck have presented full progression-free survival (PFS) results from the Phase III PAOLA-1 study of their PARP inhibitor Lynparza (olaparib) in newly-diagnosed ovarian cancer patien2019/9/19
-
Kinoxis secures US grant for opioid withdrawal treatmentThe US National Institutes of Health (NIH) has awarded a grant of up to $4.6m to University of Sydney spinout Kinoxis Therapeutics to support the development of a potential treatment for opioid withd2019/9/18
-
Roche’s Rituxan secures approval for first paediatric indicationRoche has secured approval from the US Food and Drug Administration (FDA) for Rituxan (rituximab) for children with two rare blood vessel disorders. Rituxan, in combination with glucocorticoids, ha2019/9/18
-
Roche’s Rituxan secures approval for first paediatric indication2019/9/19
-
FDA approves Darzalex combination for multiple myeloma treatmentThe US Food and Drug Administration (FDA) has approved the combined use of Darzalex (daratumumab) with bortezomib, thalidomide and dexamethasone (Vtd) as a frontline treatment for patients who are el2019/9/17
-
Avanir resolves Nuedexta kickback lawsuits for $116mCalifornia-based Avanir has resolved and settled multiple civil, criminal and administrative lawsuits in the US alleging corrupt sales and marketing practices of its drug Nuedexta (dextromethorphan H2019/9/17
-
Teva subsidiary inks distribution deal with Israeli medical marijuana product makerAs drugmakers dip their toes into the water of cannabis-based drugs, major companies have so far mostly shied away from diving in. Now, a Tevasubsidiary is looking for the on-ramp with a distribution2019/9/16
-
ECTRIMS: Novartis' Mayzent delays wheelchair use by 4-plus years for MS patientsNovartis is working to change doctors’ “psychology” around the treatment of secondary progressive multiple sclerosis (SPMS). And new disability data for its drug, Mayzent, should help its case. On av2019/9/16
-
Roche's Tecentriq scores solo win in lung cancer. But can it challenge Merck's Keytruda?Roche, late to the scene in non-small cell lung cancer, has been looking to capture share from Merck with its Tecentriq-chemo combo. And it just got one step closer to bringing its quest to the monot2019/9/12
-
Who joins Purdue on pharma's top 10 settlements list? Merck, GSK and Pfizer, for startersPurdue’s pending opioid settlement with thousands of cities and counties, worth between $10 billion and $12 billion, could rank as the largest deal ever inked by a pharma if it passes a Cleveland fed2019/9/12